# IXICO develops a new AI tool supporting radiologists to detect vascular dysfunction in Alzheimer’s disease

17 Nov 26

news

# IXICO develops a new AI tool supporting radiologists to detect vascular dysfunction in Alzheimer’s disease

Rebecca White

[  ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/news/new-ai-tool-supporting-radiologists-to-detect-vascular-dysfunction-in-alzheimers-disease/) [  ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/news/new-ai-tool-supporting-radiologists-to-detect-vascular-dysfunction-in-alzheimers-disease/) [  ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/news/new-ai-tool-supporting-radiologists-to-detect-vascular-dysfunction-in-alzheimers-disease/) [  ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/news/new-ai-tool-supporting-radiologists-to-detect-vascular-dysfunction-in-alzheimers-disease/) <a class="trigger-share-window d-md-none">  </a>

![Vascular dysfunction AI tool](/assets/blog-images/Vascular-dysfunction-AI-tool__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp)IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, announces the presentation of new research in Alzheimer’s disease (AD) at the 19th Clinical Trials on Alzheimer’s Disease Conference 2026 (CTAD).

The research developed and evaluated an artificial intelligence (AI) tool to support radiologists in detecting cerebral microbleeds (CMBs) on magnetic resonance imaging (MRI) scans. CMBs are tiny deposits of blood in the brain that appear as small dark spots on an MRI.  They are important in AD clinical trials and treatment, because pre-existing and new microbleeds are a key vascular safety concern with anti-amyloid therapies, and patients must be monitored with repeated MRI scans. Identifying CMBs by eye is time-consuming and can vary between radiologists, which is where the newly developed tool presents a potentially significant  improvement in efficiency and accuracy.

The tool works in two stages: it first finds possible microbleeds across the whole brain, then examines each one to separate true CMBs from similar-looking structures such as blood vessels. On average, the IXICO developed tool detected around 90% of the microbleeds in each participant’s scan, comparing favourably to other published results, and performed consistently across studies and imaging techniques.

Robin Wolz, Chief Scientific Officer of IXICO, commented: *“**As new treatments for Alzheimer’s disease become increasingly available, the ability to monitor patient safety accurately and efficiently is more important than ever. Detecting cerebral microbleeds is a critical part of this process but remains a time-consuming task that can be subject to variability between radiologists. Our research demonstrates the potential of AI to transform this process, delivering high levels of accuracy and consistency across different MRI techniques and patient populations. This is another example of how IXICO is applying its deep expertise in neuroscience and AI to address real-world challenges in drug development and help bring new therapies to patients.”*

[ Back to News  ](/news-and-resources/news/)

### Recents

![IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/assets/blog-images/HD-contract-win__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp)

2 Nov 26

news

[IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/news-and-resources/news/2-7-million-phase-3-contract-win-in-huntingtons-disease/)

[IXICO presents research on novel methods to reduce unwanted variability in Huntington’s disease biomarker data ](/news-and-resources/news/ixico-presents-research-on-novel-methods-to-reduce-unwanted-variability-in-huntingtons-disease-biomarker-data/)

[IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/)

[IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/)

[IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/)

### Library

[November 2026](/news-and-resources/news/archive/2026/11/)

[October 2026](/news-and-resources/news/archive/2026/10/)

[September 2026](/news-and-resources/news/archive/2026/09/)

[July 2026](/news-and-resources/news/archive/2026/07/)

[June 2026](/news-and-resources/news/archive/2026/06/)

[May 2026](/news-and-resources/news/archive/2026/05/)

[April 2026](/news-and-resources/news/archive/2026/04/)

[March 2026](/news-and-resources/news/archive/2026/03/)

[February 2026](/news-and-resources/news/archive/2026/02/)

[January 2026](/news-and-resources/news/archive/2026/01/)

[2025](/news-and-resources/news/archive/2025/)

[2024](/news-and-resources/news/archive/2024/)

[2023](/news-and-resources/news/archive/2023/)

[2022](/news-and-resources/news/archive/2022/)

[2021](/news-and-resources/news/archive/2021/)

[2020](/news-and-resources/news/archive/2020/)

[2019](/news-and-resources/news/archive/2019/)
